Medical device company ResMed Inc. RMD recently sponsored a study which shows potential treatment of obstructive sleep apnea (OSA) in patients with untreated central sleep apnea (CSA). According to ...

Michael Arzt, MD, investigated the use of ASV therapy in patients with TE-CSA and cardiovascular disease, finding it effective in reducing sleepiness and improving quality of life. It may be more ...

WASHINGTON, May 25, 2023 (GLOBE NEWSWIRE) -- Renowned medical experts at the American Thoracic Society International Conference unveiled new evidence that demonstrates treating obstructive sleep apnea ...

- Largest-ever analysis of patients with treatment-emergent central sleep apnea shows switching from CPAP to ASV significantly improves compliance - Study highlights the need to consider therapeutic ...

Breathing machines with adaptive servo-ventilation (ASV) did not improve survival or other clinical outcomes in patients with heart failure (HF) and reduced ejection fraction and sleep-disordered ...

Adaptive servo-ventilation (ASV) therapy increases mortality and should not be used to treat central sleep apnea in heart failure patients with reduced ejection fraction, the SERVE-HF trial shows.

On May 15, 2015, Respironics, Inc., a Philips business, provided the following response to ResMed's Update on Phase IV SERVE-HF Study of Adaptive Servo-Ventilation (ASV) Therapy in Central Sleep Apnea ...

There's a problem though. CPAP doesn't seem to improve CVD-related outcomes. In some cases, it's even harmful. Let's do a quick review. In 2005, the CANPAP study found CPAP didn't improve a composite ...

Continuous positive airway pressure (CPAP) and BiPAP (bi-level) therapy are used to treat sleep apnea. CPAP is the most ...

SAN DIEGO, May 13, 2015 /CNW/ -- ResMed (NYSE: RMD) today announced that SERVE-HF, a multinational, multicenter, randomized controlled Phase III trial did not meet its primary endpoint. SERVE-HF was ...